[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357977-105":59,"doc-detail-357977-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","risk-reducing-interventions-in-women-with-pathogenic-variants-in-breast-cancer-susceptibility-genes","Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes","","The study evaluates how women with germline pathogenic variants (PVs) in breast cancer susceptibility genes use risk-reducing strategies and surveillance. Using de-identified multigene panel testing data linked with claims for 12 months post-testing, investigators estimate uptake of risk-reducing mastectomy and salpingo-oophorectomy, breast MRI, and pancreatic screening. Results show breast MRI use is about one third, pancreatic screening is under 11%, and BRCA1/2 PV carriers have higher odds of surgery than other gene groups.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-reducing-interventions-in-women-with-pathogenic-variants-in-breast-cancer-susceptibility-genes/357977/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-reducing-interventions-in-women-with-pathogenic-variants-in-breast-cancer-susceptibility-genes/357977.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary goal of the study?","Question",{"text":112,"@type":113},"To examine utilization of risk-reducing strategies and surveillance in women with germline pathogenic variants in at least one of 13 breast cancer susceptibility genes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did researchers measure the uptake of interventions?",{"text":117,"@type":113},"They used claims data for 12 months after genetic testing to estimate use of risk-reducing mastectomy and salpingo-oophorectomy, breast MRI, and pancreatic screening, and then applied multivariable logistic regression.",{"name":119,"@type":110,"acceptedAnswer":120},"Which groups were more likely to pursue risk-reducing surgery?",{"text":121,"@type":113},"Women with BRCA1/2 PVs had the highest utilization of risk-reducing surgery, with higher odds than women with PVs in other breast cancer susceptibility genes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357977,1790247487,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Original Reports | Cancer Genetics  \nRisk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes  \nEmily M. Russell, PhD1  ; Sarah M. Nielsen, MS1  ; Rachel E. Ellsworth, PhD2  ; Heidi Chwan Ko, DO3  ; Rebecca A. Previs, MD, MS3,4  ; Daniel E. Pineda-Alvarez, MD2; Edward D. Esplin, MD, PhD2  ; Kevin Hughes, MD5  ; Stacy W. Gray, MD, AM6  ; Nadine M. Tung, MD7  ; and Allison W. Kurian, MD, MSc8   \nDOI [https://doi.org/10.1200/PO-26-00373](https://doi.org/10.1200/PO-26-00373)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Recommendations for clinical management of women with germline pathogenic variants (PVs) in breast cancer susceptibility genes vary by gene. The goal of this study was to examine the utilization of risk-reducing strategies and treatments in women with germline PVs in breast cancer susceptibility genes. |\n| METHODS | This cross-sectional study identified women with a PVin at least one of 13 breast cancer susceptibility genes from germline panel testing at a single commercial laboratory between 2015 and 2023. Paired health care claims data for 12 months after genetic testing were evaluated to estimate the utilization of risk-reducing mastectomy and salpingo-oophorectomy, breast magnetic resonance imaging (MRI), and pancreatic screening (magnetic resonance cholangiopancreatography or endoscopic ultrasound) in these women. Multivariable logistic regression models were used to evaluate the association of clinicodemographic factors and genetic testing results with intervention utilization. |\n| RESULTS | Of 3,959 women with a PV (2,088 cancer-free; 1,871 with primary breast cancer diagnosed ≤120 days before genetic testing), the average age at testing was 45 years, 67% were White, and 90% reported a family history of cancer. Breast MRI was used by 33% of cancer-free women and 31% of women with breast cancer after genetic testing; pancreatic screening occurred in \u003C11% of the eligible population. Women with PVs in BRCA1/2 versus other breast cancer susceptibility genes had higher odds of risk-reducing mastectomy (cancer-free: odds ratio 7.2 [95% CI, 3.5 to 14. 5]; with cancer: 6.0 [95% CI, 4.2 to 8. 5]) and salpingo-oophorectomy (cancer-free: 7.2 (95% CI, 4.6 to 11.3]; with cancer: 13.8 [95% CI, 9.7 to 19.7]) . |\n| CONCLUSION | Utilization of risk-reducing surgery was highest in women with BRCA1/2 PV. Pancreatic screening was low in all patients. Future studies are needed to examine the factors underlying these trends. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted July 22, 2026 Published August 26, 2026  \nJCO Precis Oncol 10:e2600373 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nBACKGROUND  \nGuidelines from the National Comprehensive Cancer Network (NCCN) recognize BRCA1 , BRCA2 , CDH1 , PALB2 , PTEN, STK11 , and TP53 as high-risk and ATM, BARD1 , CHEK2 , NF1 , RAD51C, and RAD51D as moderate-risk breast cancer susceptibility genes.1 Precision medicine–based strategies include risk-reducing surgeries, early detection, and treatment for individuals with germline pathogenic variants (PVs) in these genes.  \nRisk-reducing strategies vary by gene. For example, NCCN guidelines advise consideration of risk-reducing mastectomy (RRM) for women with high-risk breast cancer gene PVs, yet not for women with moderate-risk gene PVs.1 Risk-  \nreducing salpingo-oophorectomies (RRSO) are recommended for women with PVs in ovarian cancer risk genes: BRCA1 , BRCA2 , PALB2 , RAD51C, and RAD51D.  \nFor early breast cancer detection, women with highor moderate-risk gene PVs are recommended to have breast magnetic resonance imaging (MRI) in addition to mammogram.1 ATM, BRCA1 , BRCA2 , PALB2 , STK11 , and TP53 PVs confer increased risk of pancreatic cancer, and endoscopic ultrasound (EUS) and/or magnetic resonance cholangiopancreatography (MRCP) are offered for early detection.1  \nAfter breast cancer diagnosis, genetic results","cbCaiczGptO6W4uZ","https://ap.wps.com/l/cbCaiczGptO6W4uZ","pdf",728294,12,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Background\n## Guidelines and gene risk categories\n# Context\n## Key objective\n## Knowledge generated\n## Relevance\n# Methods\n## Data sources","[{\"question\":\"What was the primary goal of the study?\",\"answer\":\"To examine utilization of risk-reducing strategies and surveillance in women with germline pathogenic variants in at least one of 13 breast cancer susceptibility genes.\"},{\"question\":\"How did researchers measure the uptake of interventions?\",\"answer\":\"They used claims data for 12 months after genetic testing to estimate use of risk-reducing mastectomy and salpingo-oophorectomy, breast MRI, and pancreatic screening, and then applied multivariable logistic regression.\"},{\"question\":\"Which groups were more likely to pursue risk-reducing surgery?\",\"answer\":\"Women with BRCA1/2 PVs had the highest utilization of risk-reducing surgery, with higher odds than women with PVs in other breast cancer susceptibility genes.\"}]","Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes | PDF",1790132403]